Results 71 to 80 of about 211,753 (383)

Geriatric pharmacotherapy : optimisation through integrated approach in the hospital setting [PDF]

, 2016
Since older patients are more vulnerable to adverse drug-related events, there is a need to ensure appropriate prescribing in these patients in order to prevent misuse, overuse and underuse of drugs.
A Corsonello, A Jha, A Leendertse, A Somers, A Somers, A Somers, A Spinewine, A Spinewine, A Spinewine, American Geriatrics Society, B Basger, B Berenguer, B Lund, B Strom, B Tangiisuran, C Lindley, C Naugler, C Rancourt, C Scullin, C Zhan, D Classen, E Hajjar, G Batty, G Ellis, G Onder, G Onder, G Onder, G Onder, H Beijer, H Hamilton, I Eland, J Hanlon, J Hanlon, J Klopotowska, J Lazarou, J Schnipper, J Wolfstadt, K Perehudoff, K Schmader, L Leape, M Beers, M Laroche, M O’Connor, M Passarelli, M Petrovic, M Petrovic, M Pirmohamed, M Steinman, NS Wenger, P Bemt van den, P Gallagher, P Gallagher, P Lampela, P McLeod, P Rochon, R Cipolle, R Page, S Holt, S Kaur, S Kucukarslan, S Rognstad, T Field, T Field, W Winit-Watjana   +63 more
core   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008–2017

Journal of Korean Medical Science, 2020
Severe and life-threatening drug eruptions include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). One class of medications that has been highly associated with such drug eruptions is antiepileptic drugs (AEDs).
Hyun Kyung Kim, Dae Yeon Kim, Eun-Kee Bae, Dong Wook Kim   +3 more
openaire   +2 more sources

A Prospective Analysis of Adverse Drug Reactions in a South Indian Hospital [PDF]

, 2009
Adverse drug reactions are a great cause of concern to the medical profession, the patients and the pharmaceutical industry. However ADR reporting and monitoring is yet to catch up in India.
Adhikari, P, Padmaja, U, Pereira, P
core  

Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus [PDF]

, 2016
Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects.
Attarbaschi, Andishe, Barzilai, Shlomit, Escherich, Gabriele, Frandsen, Thomas Leth, Halsey, Christina, Hough, Rachael, Jeha, Sima, Kato, Motohiro, Liang, Der-Cherng, Mikkelsen, Torben Stamm, Moricke, Anja, Niinimaki, Riitta, Piette, Caroline, Putti, Maria Caterina, Raetz, Elizabeth, Schmiegelow, Kjeld, Silverman, Lewis B., Skinner, Roderick, Tuckuviene, Ruta, van der Sluis, Inge, Zapotocka, Ester   +20 more
core   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

A Multi-Agent System for Reporting Suspected Adverse Drug Reactions

Online Journal of Public Health Informatics, 2014
Adverse drug reactions (ADRs) represent a serious worldwide public health problem. Current post-marketing ADR detection approaches largely rely on spontaneous reports filed by various healthcare professionals such as physicians, pharmacists et.al.. Underreporting is a serious deficiency of these methods - the actually reported adverse events represent ...
Yanqing Ji, Fangyang Shen, See-Yan Lau, John Tran   +3 more
openaire   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Patient safety in Europe: medication errors and hospital-acquired infections [PDF]

, 2008
The Report was commissioned by the European Federation of Nurses Associations (EFN) in November 2007 in order to support its policy statements on Patient Safety (June 2004).
Burke, J., Smith, L.N., Sveinsdóttir, H., Willman, A.   +3 more
core   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source